Amneal receives u.s. fda approval of sodium oxybate oral solution

Bridgewater, n.j, sept. 11, 2025 (globe newswire) -- amneal pharmaceuticals, inc. (“amneal” or the “company”) today announced the u.s. food and drug administration (fda) approval of amneal's sodium oxybate oral solution 500 mg/ml abbreviated new drug application (anda) which references jazz pharmaceuticals' xyrem®.
AMRX Ratings Summary
AMRX Quant Ranking